Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ROIV by emailGet an email when ROIV pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ROIV, unsubscribe in one click. Privacy
📣 What ROIV Says Is Next
second half of · “Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.”
Company press release, Apr 2, 2026 · SEC filing
2H 2026 · “Upcoming Brepocitinib Catalysts Over the Next 18 Months Pivotal / Potentially Registrational Proof of Concept / Other Early 2026 Expected NDA filing in DM 2026 2H 2026 Topline data in NIU 1H 2027 Potential sNDA filing in NIU 1H 2026 Topline data in CS 63 2027 Early 2027 Potential commercial launch in DM Note: All drugs are investigational and subject to regulatory approvals.”
Company press release, Dec 11, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ROIV picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ROIV and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.